

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claim 1 (currently mended): A method for inhibiting a condition characterized by monocytic infiltrates, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor antagonist is an antibody or binding fragment thereof which binds to an MCP-1 receptor polypeptide.

Claim 2 (original): The method of claim 1, wherein said MCP-1 receptor polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

Claim 3 (original): The method of claim 1, wherein said MCP-1 receptor antagonist is administered to said patient as a pharmaceutical composition.

Claim 4 (original): The method of claim 3, wherein said pharmaceutical composition contains about 10 µg/ml to about 1 mg/ml of the antagonist.

Claim 5 (canceled).

Claim 6 (currently amended): The method of claim ~~5~~ 1, wherein said antibody or binding fragment thereof is administered to said patient as a pharmaceutical composition.

Claim 7 (currently amended): The method of claim ~~5~~ 1, wherein said antibody is a monoclonal antibody.

Claim 8 (currently amended): The method of claim ~~5~~ 1, wherein said antibody is a humanized antibody.

Claim 9 (original): The method of claim 1, wherein said condition is atherosclerosis.

Claim 10 (currently amended): A method for inhibiting MCP-1 receptor polypeptide, wherein said method comprises administering to a patient a therapeutically effective amount of an MCP-1 receptor antagonist in a suitable pharmaceutical carrier, wherein said MCP-1 receptor antagonist is an antibody or binding fragment thereof which binds to said MCP-1 receptor polypeptide.

Claim 11 (original): The method of claim 10, wherein said MCP-1 receptor polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

Claim 12 (original): The method of claim 10, wherein said MCP-1 receptor antagonist is administered to said patient as a pharmaceutical composition.

Claim 13 (original): The method of claim 12, wherein said pharmaceutical composition contains about 10 µg/ml to about 1 mg/ml of the antagonist.

Claim 14 (canceled).

Claim 15 (currently amended): The method of claim 14 10, wherein said antibody or binding fragment thereof is administered to said patient as a pharmaceutical composition.

Claim 16 (currently amended): The method of claim 14 10, wherein said antibody is a monoclonal antibody.

Claim 17 (currently amended): The method of claim 14 10, wherein said antibody is a humanized antibody.